Barclays
CLDX icon

Barclays’s Celldex Therapeutics CLDX Stock Holding History

Barclays’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5,867
Closed -$205K – 6994
2018
Q1 		$205K Buy
+5,867
New +$227K ﹤0.01% 4810
2015
Q2 		– Sell
-1,713
Closed -$694K – 7027
2015
Q1 		$694K Sell
1,713
-3,434
-67% -$1.23M ﹤0.01% 3296
2014
Q4 		$1.39M Buy
+5,147
New +$1.28M ﹤0.01% 2874
2014
Q1 		– Sell
-8,333
Closed -$3M – 7578
2013
Q4 		$3M Buy
8,333
+4,293
+106% +$1.65M ﹤0.01% 2268
2013
Q3 		$2.12M Buy
+4,040
New +$1.39M ﹤0.01% 2504

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return